VIVA Circle | Recent Developments of Viva BioInnovator's Portfolio Companies (Q4 2025 – Q1 2026)

Arthrosi Therapeutics, Inc., headquartered in San Diego, California, USA, is focused on the development of Pozdeutinurad (AR882). As a potential best-in-class, highly potent, and selective next-generation URAT1 inhibitor, the drug aims to lower serum uric acid levels in gout patients, reduce flares, and dissolve tophi. The rights to Pozdeutinurad in Greater China are held by Yipinhong Pharmaceutical. For more information, please visit arthrosi.com.

Proviva Therapeutics was founded in 2019 as a clinical-stage biotechnology company focused on the next generation of cancer immunotherapy. Relying on its self-developed "CROSSOVER" prodrug platform, the company is committed to solving the long-standing issue of peripheral toxicity associated with cytokine-based drugs. At the same time, by integrating a continuously innovative technology system, including the "MUSICA" multifunctional effector cell activation platform, it aims to build a globally competitive product pipeline to address significant unmet clinical needs in the field of cancer treatment. The company's core product, PTX-912, has entered the clinical stage, and its related technologies have received multiple patent authorizations, demonstrating the product’s unique first-in-class mechanism and global development potential.

TJ Biopharma is a full-chain biotechnology company focusing on innovative therapies in the fields of autoimmune diseases, cancer immunology, and metabolic disorders. Based in China, the company has established an end-to-end industrial chain encompassing R&D centers in Shanghai and Beijing, as well as a GMP production base in Hangzhou. It has successfully built a differentiated and multi-tiered clinical pipeline along with a preclinical pipeline. Two products from the first tier (Fizezumab and Etanercept Growth Hormone α) have entered the product marketing application stage, while another three innovative products are expected to enter Phase III clinical trials by 2025. For more information, please visit: TJBio.com.

Ophidion, Inc. is an early-stage biopharmaceutical company focused on the central nervous system (CNS) field, dedicated to developing non-invasive therapeutic solutions for neurodegenerative diseases. Its proprietary carrier technology aims to deliver large molecule drugs and oligonucleotides to the brain through intravenous administration. The company is currently advancing research and development projects related to Huntington's disease, Alzheimer's disease, and Parkinson's disease. For more information, please visit ophidion.com.

AmacaThera is a biotechnology company focused on next-generation hydrogel drug delivery solutions. Its proprietary platform enables precise drug localization and tunable release within the body by controlling the phase transition of drugs from liquid to gel, allowing sustained release over days to weeks based on different therapeutic needs. Leveraging this platform, AmacaThera collaborates with pharmaceutical and biotech companies to co-develop innovative long-acting drug delivery solutions that enhance efficacy, improve patient experience, and reduce systemic exposure risks. The platform offers scalable and cost-effective manufacturing advantages, providing strong support for the company’s collaboration models across multiple therapeutic areas. For more information, please visit: www.amacathera.com.

Domain Therapeutics is a clinical-stage biopharmaceutical company focused on developing highly differentiated therapeutic strategies targeting GPCRs, a key category of drug targets. The company has established a robust pipeline of registered and clinical-stage R&D programs aimed at addressing significant unmet medical needs, particularly in the fields of immuno-oncology and inflammation, offering innovative treatment options to patients. Domain's core pipeline includes a best-in-class Treg-depleting anti-CCR8 antibody and a first-in-class PAR2-biased antagonist. These innovative therapies are driving the continuous growth of the company’s value, positioning it as a leader in the rapidly expanding and highly competitive market.

Basking Biosciences is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of life-threatening thrombosis. The company’s novel therapies aim to significantly enhance the safety and efficacy of treatments, enabling more patients to receive timely care. Its lead candidate drug, BB-031, is the world’s first thrombolytic therapy featuring rapid onset, short duration of action, and a specific reversal agent, currently in development for the treatment of acute ischemic stroke. By targeting von Willebrand Factor (vWF), a key driver of thrombus formation, BB-031 demonstrates highly targeted and potent thrombolytic activity. Combined with its reversal agent, BB-031 holds the potential to provide more stroke patients with life-saving treatment in a timely manner after symptom onset. For more information, please visit www.baskingbiosciences.com.

Disclaimer

Information related to the incubated companies is provided by the incubated companies and has not been independently verified by our company. In any case, our company will not assume any direct or indirect responsibility (whether in tort, contractual liability, or otherwise) for any loss or damage caused by inaccurate or omitted information in this press release or the use of the information contained herein.